Podcast: Getting Ahead of the ALS Curve Through Early Detection and Intervention: Module 2: Disease-Modifying Therapies for
Tracking # 20-954155
Course overview
In this podcast, hear about expert strategies for weighing the options of disease-modifying therapies for amyotrophic lateral sclerosis (ALS)! Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts Hospital and Healey & AMG Center for ALS, and Associate Professor of Physical Medicine and Rehabilitation (PM&R) at Spaulding Rehabilitation Hospital of Harvard Medical School, will discuss the latest data on novel disease-modifying therapies for slowing ALS progression, prolonging survival, and improving quality of life. Listen to the podcast now!
Subject areas
This course counts toward the state boards and subject areas below.
New Hampshire Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
Certified Registered Nurse Anesthetist
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
North Dakota Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Disclosure statements
i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Sabrina Paganoni, MD, PhD, discloses that she has served as a sonsultant for Amylyx, Arrowhead, Cytokinetics, and Eikonizo, and she has received grants/research support from Calico, Clene, Denali, Prilenia, Seelos, and UCB.
i3 Health has mitigated all relevant financial relationships.